Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation.
CD25
STAT5 activation
T cell activation
T cell proliferation
flow cytometry
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
12
2018
accepted:
18
03
2019
entrez:
27
4
2019
pubmed:
27
4
2019
medline:
22
9
2020
Statut:
epublish
Résumé
Here we present a simple and sensitive flow cytometric-based assay to assess T cell proliferation. Given the critical role STAT5A phosphorylation in T cell proliferation, we decided to evaluate phosphorylation of STAT5A as an indicator of T cell proliferation. We determined pSTAT5A in T cell treated with either CD3/CD28 or PHA. After stimulation, T cells from adult healthy donors displayed a strong long-lasting phosphorylation of STAT5A, reaching a peak value after 24 h. The median fluorescence intensity (MFI) of pSTAT5A increased from 112 ± 17 to 512 ± 278 (CD3/CD28) (24 h) and to 413 ± 123 (PHA) (24 h), the IL-2 receptor-α (CD25) expression was greatly enhanced and after 72 h T cell proliferation amounted to 52.3 ± 10.3% (CD3/CD28) and to 48.4 ± 9.7% (PHA). Treatment with specific JAK3 and STAT5 inhibitors resulted in a complete blockage of phosphorylation of STAT5A, CD25 expression, and suppression of T cell proliferation. Compared with currently available methods, STAT5A phosphorylation is well-suited to predict T cell proliferation. Moreover, the method presented here is not very time consuming (several hours) and delivers functional information from which conclusions about T cell proliferation can be drawn.
Identifiants
pubmed: 31024554
doi: 10.3389/fimmu.2019.00722
pmc: PMC6460883
doi:
Substances chimiques
STAT5 Transcription Factor
0
Janus Kinase 3
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
722Références
Oncogene. 2000 May 15;19(21):2566-76
pubmed: 10851055
J Immunol Methods. 2000 Sep 21;243(1-2):147-54
pubmed: 10986412
Mol Pharmacol. 2000 Nov;58(5):1057-66
pubmed: 11040054
Biochim Biophys Acta. 2000 Oct 20;1498(1):1-18
pubmed: 11042346
J Immunol Methods. 2001 Jul 1;253(1-2):95-112
pubmed: 11384672
Immunol Cell Biol. 2002 Aug;80(4):351-7
pubmed: 12121224
Arthritis Res Ther. 2004;6(4):159-68
pubmed: 15225360
Cytokine Growth Factor Rev. 2004 Dec;15(6):435-55
pubmed: 15561601
Nat Rev Immunol. 2005 Jun;5(6):472-84
pubmed: 15928679
Science. 2005 Nov 18;310(5751):1159-63
pubmed: 16293754
PLoS One. 2007 Sep 26;2(9):e935
pubmed: 17895976
J Immunol. 2007 Oct 15;179(8):5301-8
pubmed: 17911616
J Clin Invest. 2008 Nov;118(11):3564-73
pubmed: 18982163
Cytometry A. 2010 Jul;77(7):607-13
pubmed: 20583270
J Immunol Methods. 2011 Feb 1;364(1-2):33-9
pubmed: 21036178
Cytometry A. 2011 Feb;79(2):95-101
pubmed: 21265003
Curr Opin Rheumatol. 2012 Sep;24(5):515-21
pubmed: 22820513
Cytometry A. 2012 Nov;81(11):1005-11
pubmed: 22997026
N Engl J Med. 2013 Jan 10;368(2):161-70
pubmed: 23301733
Evid Based Complement Alternat Med. 2013;2013:435916
pubmed: 23533483
Cytometry B Clin Cytom. 2013 May;84(3):135-42
pubmed: 23554222
Cytometry B Clin Cytom. 2014 May;86(3):191-206
pubmed: 24488780
PLoS One. 2014 Jan 30;9(1):e86790
pubmed: 24497979
Clin Exp Immunol. 2015 Jul;181(1):29-38
pubmed: 25736842
J Interferon Cytokine Res. 2016 Apr;36(4):226-37
pubmed: 26716518
J Immunol Methods. 2016 Mar;430:10-20
pubmed: 26780292
PLoS One. 2016 Dec 9;11(12):e0167215
pubmed: 27936140
F1000Res. 2017 Jan 11;6:32
pubmed: 28163905
J Allergy Clin Immunol. 2017 Nov;140(5):1439-1441.e9
pubmed: 28601682
Cytometry. 1997 Jan 1;27(1):71-6
pubmed: 9000587